A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1) (VIJAY-1)
A Phase 1, Open Label, Dose Escalation, Multicenter Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Oral AUR104 in Patients With Select Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)
Sponsor: Aurigene Discovery Technologies Limited
Terminated
Patient recruitment problems
Other terminated trials from Aurigene Discovery Technologies Limited
- Advanced Malignant Neoplasm · Feb 2026
- Colorectal Cancer · Feb 2026
- Gastroesophageal Junction Adenocarcinoma · Dec 2025
- Acute Myeloid Leukemia · Nov 2024
- Hodgkin Lymphoma · Mar 2024
More terminations from Aurigene Discovery Technologies Limited
This observational or N/A phase trial investigates Select Relapsed/Refractory Lymphoid Malignancies and is currently terminated or withdrawn. Aurigene Discovery Technologies Limited leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Study Description(click to expand)This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The dose escalation will be conducted in a rule-based manner in patients who do not have any available curative treatment options and have exhausted all effective therapies available locally. At a minimum, the patients must have relapsed or refractory disease to at least 2 prior lines of systemic therapies for NHL or CLL, or Hodgkin's disease. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104. In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The dose escalation will be conducted in a rule-based manner in patients who do not have any available curative treatment options and have exhausted all effective therapies available locally. At a minimum, the patients must have relapsed or refractory disease to at least 2 prior lines of systemic therapies for NHL or CLL, or Hodgkin's disease. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104. In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.
Status Flow
Change History
4 versions recorded-
Apr 18, 2026 — Present [daily]
Terminated
Status: Recruiting → Terminated · Phase: PHASE1 → None
-
Jan 2026 — Apr 2026 [monthly]
Recruiting PHASE1
-
Sep 2025 — Jan 2026 [monthly]
Recruiting PHASE1
-
Feb 2025 — Sep 2025 [monthly]
Recruiting PHASE1
First recorded
Dec 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
This is a multicenter, open-label, Phase 1 study of AUR104 in adult patients with select Relapsed/Refractory (R/R) Lymphoid Malignancies. The main objective of the study is to evaluate the safety and tolerability of the study drug AUR104.In this study, safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AUR104 will be evaluated in dose escalation manner.
Contact Information
- Aurigene Discovery Technologies Limited
For direct contact, visit the study record on ClinicalTrials.gov .